Sweden
· Delayed Price · Currency is SEK ODI Pharma AB Statistics
Total Valuation
ODI Pharma AB has a market cap or net worth of SEK 42.65 million. The enterprise value is 37.29 million.
| Market Cap | 42.65M |
| Enterprise Value | 37.29M |
Important Dates
The next estimated earnings date is Friday, May 23, 2025.
| Earnings Date | May 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ODI Pharma AB has 15.92 million shares outstanding. The number of shares has increased by 0.38% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 15.92M |
| Shares Change (YoY) | +0.38% |
| Shares Change (QoQ) | +2.28% |
| Owned by Insiders (%) | 91.45% |
| Owned by Institutions (%) | n/a |
| Float | 1.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.98 |
| PB Ratio | 95.85 |
| P/TBV Ratio | 95.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -9.26 |
| EV / Sales | 1.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.07
| Current Ratio | 1.07 |
| Quick Ratio | 1.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.22 |
Financial Efficiency
Return on equity (ROE) is -324.80% and return on invested capital (ROIC) is -150.27%.
| Return on Equity (ROE) | -324.80% |
| Return on Assets (ROA) | -26.68% |
| Return on Invested Capital (ROIC) | -150.27% |
| Return on Capital Employed (ROCE) | -670.26% |
| Revenue Per Employee | 21.50M |
| Profits Per Employee | -4.03M |
| Employee Count | 1 |
| Asset Turnover | 3.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -58.10% in the last 52 weeks. The beta is 0.66, so ODI Pharma AB's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | -58.10% |
| 50-Day Moving Average | 2.68 |
| 200-Day Moving Average | 4.05 |
| Relative Strength Index (RSI) | 52.23 |
| Average Volume (20 Days) | 1,465 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ODI Pharma AB had revenue of SEK 21.50 million and -4.03 million in losses. Loss per share was -0.26.
| Revenue | 21.50M |
| Gross Profit | 4.37M |
| Operating Income | -2.98M |
| Pretax Income | -3.84M |
| Net Income | -4.03M |
| EBITDA | -2.98M |
| EBIT | -2.98M |
| Loss Per Share | -0.26 |
Balance Sheet
The company has 5.36 million in cash and n/a in debt, giving a net cash position of 5.36 million or 0.34 per share.
| Cash & Cash Equivalents | 5.36M |
| Total Debt | n/a |
| Net Cash | 5.36M |
| Net Cash Per Share | 0.34 |
| Equity (Book Value) | 445,012 |
| Book Value Per Share | 0.03 |
| Working Capital | 439,435 |
Cash Flow
| Operating Cash Flow | -2.91M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 20.31%, with operating and profit margins of -13.87% and -18.74%.
| Gross Margin | 20.31% |
| Operating Margin | -13.87% |
| Pretax Margin | -17.86% |
| Profit Margin | -18.74% |
| EBITDA Margin | -13.86% |
| EBIT Margin | -13.87% |
| FCF Margin | n/a |
Dividends & Yields
ODI Pharma AB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.38% |
| Shareholder Yield | -0.38% |
| Earnings Yield | -9.45% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |